首页> 中文期刊> 《广西医学 》 >尼妥珠单抗联合顺铂和三维适形放疗治疗鼻咽癌的临床研究

尼妥珠单抗联合顺铂和三维适形放疗治疗鼻咽癌的临床研究

             

摘要

目的:观察尼妥珠单抗联合三维适形和顺铂同步放化疗治疗鼻咽癌的疗效及其毒副作用。方法对照组24例采用三维适形放疗和顺铂方案同步放化疗,实验组20例在对照组放化疗的基础上加用尼妥珠单抗治疗。比较两组疗效及不良反应等。结果实验组近期疗效优于对照组(P<0.05),实验组和对照组治疗有效率分别为75.00%、50.00%,两组不良反应发生率无差异( P>0.05)。结论尼妥珠单抗联合顺铂和三维适形放疗治疗鼻咽癌患者疗效良好,并未增加放化疗相关不良反应。%Objective To observe the efficacies and adverse effects of nimotuzumab in combination with concurrent chemoradiotherapy of three-dimensional conformal radiotherapy and cisplatin on nasopharyngeal carcinoma (NPC).Methods Twenty-four cases in the control group were treated with concurrent chemoradiotherapy of three -dimensional conformal radiotherapy and cisplatin ,20 cases in the experimental group were given nimotuzumab besides the therapy conducted in the control group .The efficacy and adverse reactions were compared between two groups .Results The short-term efficacy of experimental group was better than that of control group (P<0.05).The effective rates of experimental group ,control group were 75 .00%,50 .00%,respectively .There was no significantly difference in the incidence of adverse reactions between two groups ( P>0 .05 ) .Conclusion Nimotuzumab combined with cisplatin and three-dimensional conformal radiotherapy is of good effects ,which does not aggravate the adverse reactions of chemoradiotherapy .

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号